Stock Update (NYSE:JNJ): Johnson & Johnson Pharmaceutical Segment to Continue Driving Above-Industry Growth with Plans to File More than 10 New Products by 2019, Each with Potential to Exceed $1 Billion in Revenue

[PR Newswire] – NEW BRUNSWICK, N.J., May 20, 2015 /PRNewswire/ — At a meeting today with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) will announce plans . . . → Read More: Stock Update (NYSE:JNJ): Johnson & Johnson Pharmaceutical Segment to Continue Driving Above-Industry Growth with Plans to File More than 10 New Products by 2019, Each with Potential to Exceed $1 Billion in Revenue Similar Articles: Stock Update: Johnson & Johnson (NYSE:JNJ) – U.S. FDA warns on newer class of type 2 diabetes drugs Company Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson to Host Investor Conference Call on First-Quarter Results Company Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson Announces Binding Offer from Cardinal Health to Acquire Cordis